Table 1.
Correlation between LGR5 expression and clinicopathologic features in primary breast cancer
| Variable | Patients N (%) | LGR5 intensity | R | P value | |||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | ||||
| All | 401 (100) | 69 | 157 | 151 | 24 | ||
| Age | |||||||
| < 50 | 67 (16.7) | 8 | 32 | 23 | 4 | - 0.003 | 0.95 |
| ≥ 50 | 334 (83.3( | 61 | 125 | 128 | 20 | ||
| Tumor size | |||||||
| ≤ 20 mm | 232 (57.9) | 32 | 82 | 104 | 14 | −0.162 | 0.001 |
| > 20 mm | 169 (42.1) | 37 | 75 | 47 | 10 | ||
| Ki67 | |||||||
| 0–10% | 139 (36.4) | 27 | 48 | 57 | 7 | 0.012 | 0.81 |
| 11–25% | 127 (33.2) | 23 | 45 | 43 | 9 | ||
| > 25% | 116 (30.4) | 17 | 48 | 43 | 8 | ||
| NHG | |||||||
| 1 | 93 (23.3) | 13 | 31 | 44 | 5 | −0.100 | 0.047 |
| 2 | 161 (40.3) | 30 | 58 | 63 | 10 | ||
| 3 | 146 (36.5) | 26 | 67 | 44 | 9 | ||
| Nodal metastasis | |||||||
| No | 208 (57.8) | 24 | 86 | 87 | 11 | −0.162 | 0.002 |
| Yes | 152 (42.2) | 38 | 60 | 49 | 5 | ||
| ER | |||||||
| ≤ 10% | 61 (15.2) | 3 | 23 | 26 | 9 | −0.166 | 0.001 |
| > 10% | 340 (84.4) | 66 | 134 | 125 | 15 | ||
| PR | |||||||
| ≤ 10% | 125 (31.2) | 20 | 45 | 48 | 12 | −0.70 | 0.16 |
| > 10% | 276 (68.8) | 49 | 112 | 103 | 12 | ||
| Luminal A | 214 (53.6) | 41 | 87 | 77 | 9 | −0.092 | 0.065 |
| Luminal B | 35 (8.8) | 8 | 13 | 13 | 1 | −0.043 | 0.40 |
| HER2 | 22 (5.5) | 0 | 9 | 10 | 3 | 0.110 | 0.028 |
| Basal | 136 (34.3) | 15 | 55 | 55 | 11 | 0.103 | 0.040 |
Abbreviations: LGR5 Leucine-rich repeat-containing G-protein coupled receptor 5, R correlation coefficient, NHG Nottingham histologic score, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor. Spearman correlation, two-tailed- value. Bold indicates P -value < 0.05